Panic Disorder Market Report and Forecast 2024-2032

Panic Disorder Market Outlook

The panic disorder market size in the 7 major markets was valued at USD 9.7 billion in 2023, driven by the increased emphasis on improving mental health. The market is expected to grow at a CAGR of 4.18% during the forecast period of 2024-2032, with the values likely to rise from USD 10.1 billion in 2024 to USD 14 billion by 2032.

Panic Disorder: Introduction

Panic disorder is characterized by a condition with recurring and frequent panic attacks. They are repeated episodes of intense anxiety and fear, accompanied by physical symptoms like nausea, trembling, sweating and palpitations. Symptoms can also be triggered using amphetamines, cocaine, marijuana, hallucinogens, alcohol, and other drugs. Panic disorders are frequently treated through antidepressants, benzodiazepines, cognitive as well as behavioral therapies.

Panic Disorder Market Analysis

Pharmacological intervention is one of the most common panic disorder treatments. Over the years, there has been development of several medications like diazepam, alprazolam, clonazepam, paroxetine, venlafaxine, clomipramine, fluoxetine and adinazolam, helping many patients cope with the symptoms. Owing to the high panic disorder market demand, the FDA has also approved several medications such as Cymbalta (duloxetine delayed-release capsules), Effexor XR (venlafaxin HCL) and Zoloft (sertraline HCl) among others.

Along with pharmaceuticals, CBT (cognitive behavioral therapy) has shown promising results for treating panic disorders. Panic-focused psychodynamic psychotherapy, eye movement desensitization and reprocessing (EMDR) therapy and applied relaxation training (ART) are frequently applied, depending on the symptoms of the patients. Meditation is also promoted as a treatment for relieving anxiety symptoms.

The increasing integration of digital and artificial intelligence enabled tools into the medical ecosystem has propelled the panic disorder market growth. Smartphone apps to help manage anxiety have emerged in the market. For instance, the Mindable app, developed by professors at Constructor University in Bremen has been approved to manage panic disorder and agoraphobia. Similarly, Apple has launched their ‘Rootd’, facilitating the consumers with panic conditions.

Panic Disorder Market Segmentation

Market Breakup by Type

• Agoraphobia

• Social Anxiety Disorder (SAD)

• Obsessive-Compulsive Disorder (OCD)

• Bipolar Disorder

• Post-Traumatic Stress Disorder (PTSD)

• Specific Phobias, Generalized Anxiety Disorder (GAD)

• Major Depressive Disorder (MDD)

• Others

Market Breakup by Therapy

• Electroconvulsive Therapy ECT

• Cognitive-Behavioral Therapy (CBT)

Market Breakup by Drug Class

• Benzodiazepines (BZD)

• Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)

• Monoamine Oxidase Inhibitors (MAOIs)

• Anti-Depressants

• Tricyclic Antidepressants (TCAs)

• Pregabalin

• Buspirone

• Sertraline

• Others

Market Breakup by Route of Administration

• Oral

• Parenteral

Market Breakup by Region

• United States

• EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom

• Japan

Panic Disorder Market Overview

The United States hold a significant panic disorder market share and is likely to continue dominating the market in the coming years as well. With prominent companies prevailing in the region, the frequency of drug development and approvals is high. There is rising awareness on mental health related issues with government and private foundations stepping in with campaigns and seminars to impart relevant knowledge on the issues.

In Europe, traditional techniques like aromatherapy and meditation are on the rise. The EU commission has announced a hefty investment of 6 million euros as a part of their mental health strategy. Moreover, workplace mental health initiatives have also been taken on the psychosocial risks of burnout in offices.

The Asia Pacific panic disorder market value is anticipated to grow with reducing stigmatization of mental health issues. With the help non-profit organizations and government campaigns, the masses are getting more aware about the condition. Moreover, the region is also experiencing improvements in the healthcare ecosystem to provide better treatment alternatives to the patients.

Panic Disorder Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Teva Pharmaceutical Industries Ltd

• Sun Pharmaceutical Industries Ltd.

• Mylan

• AstraZeneca

• Abbott

• Baxter

• Bristol-Myers Squibb Company

• Eli Lilly and Company

• F. Hoffmann-La Roche Ltd

• GlaxoSmithKline plc

• Recordati S.p.A.

• Boehringer Ingelheim International GmbH.

• Neurocrine Biosciences, Inc

• Recordati S.p.A.

• Sanofi

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report